A major goal of current clinical research in Parkinson's disease (PD) is the validation and
standardization of biomarkers enabling early diagnosis, predicting outcomes, understanding …

Importance Urate elevation, despite associations with crystallopathic, cardiovascular, and
metabolic disorders, has been pursued as a potential disease-modifying strategy for …

Abstract The US Food and Drug Administration (FDA) has publicly recognized the
importance of improving drug development efficiency, deeming translational biomarkers a …

Imaging biomarkers play a wide-ranging role in clinical trials for neurological disorders. This
includes selecting the appropriate trial participants, establishing target engagement and …

In recent years, a precision medicine approach, which customizes medical treatments based
on patients' individual profiles and incorporates variability in genes, the environment, and …

As therapeutic trials target early stages of Parkinson's disease (PD), appropriate patient
selection based purely on clinical criteria poses significant challenges. Members of the …

Biomarkers are important tools in medicines development and clinical practice. Besides their
use in clinical trials, such as for enrichment of patients, monitoring safety or response to …

Efforts for sharing individual clinical data are gaining momentum due to a heightened
recognition that integrated data sets can catalyze biomedical discoveries and drug …

目的探讨脑多巴胺转运蛋白显像剂11 C-甲基-N-2β-甲基酯-3β-(4-F-苯基) 托烷(11 C-β-CFT)
的PET/CT 显像在早期帕金森病诊断中的临床应用价值. 方法将第一步反应生成的11 C-CH 3 I …

Rare diseases impact the lives of an estimated 350 million people worldwide, and yet about
90% of rare diseases remain without an approved treatment. New technologies have …